Narkolepsja – Epidemiologia

Narkolepsja (ang. narcolepsy) jest przewlekłym zaburzeniem neurologicznym, charakteryzującym się nadmierną sennością w ciągu dnia i dodatkowymi objawami, które mogą obejmować katapleksję (nagłą utratę napięcia mięśniowego), zaburzenia snu nocnego, paraliż przysenny oraz omamy hipnagogiczne i hipnopompiczne. Dane epidemiologiczne dotyczące narkolepsji są zróżnicowane, w zależności od badanej populacji i stosowanej metodologii badawczej.¹²

Chorobowość narkolepsji

Chorobowość (rozpowszechnienie) narkolepsji typu 1 (NT1, z katapleksją) według większości badań mieści się w zakresie od 25 do 50 przypadków na 100 000 osób. Natomiast w przypadku narkolepsji typu 2 (NT2, bez katapleksji) chorobowość szacuje się na poziomie od 20 do 34 przypadków na 100 000 osób.¹²

W Stanach Zjednoczonych rozpowszechnienie narkolepsji szacuje się na około 0,02-0,18% populacji, co przekłada się na około 200 000 chorych Amerykanów (około 1 na 2000 osób). Jednakże badania sugerują, że spośród 200 000 osób z diagnozą narkolepsji, nawet 150 000 pozostaje niezdiagnozowanych.¹²

Dane dotyczące chorobowości narkolepsji znacznie różnią się w zależności od regionu geograficznego. W badaniu przeprowadzonym w USA w 2023 roku chorobowość narkolepsji z katapleksją oszacowano na 12,6 przypadków na 100 000 osób, a narkolepsji bez katapleksji na 25,1 przypadków na 100 000 osób. Łącznie daje to 37,7 przypadków narkolepsji na 100 000 osób w populacji USA (około 126 191 osób).¹

W Europie i USA chorobowość narkolepsji szacuje się na około 19-56 przypadków na 100 000 osób, podczas gdy w niektórych regionach świata współczynniki są znacznie niższe (np. w Izraelu – 0,2 na 100 000) lub znacznie wyższe (np. w Japonii – do 590 na 100 000).¹²³

W Niemczech, według badania DORMIO, standaryzowana względem wieku i płci chorobowość narkolepsji wynosiła 5,3 przypadków na 100 000 osób, gdy uwzględniano tylko pacjentów zdiagnozowanych przez specjalistów, oraz 9,1 na 100 000, gdy włączano również pacjentów zdiagnozowanych przez lekarzy podstawowej opieki zdrowotnej. Ogólnie, chorobowość narkolepsji w Niemczech oszacowano na 3,1-9,1 przypadków na 100 000 osób.¹²

Zapadalność na narkolepsję

Dane dotyczące zapadalności (liczby nowych przypadków) na narkolepsję są bardziej ograniczone. W badaniach populacyjnych roczna zapadalność na narkolepsję typu 1 (NT1) szacowana jest na 0,74 przypadków na 100 000 osobolat. Szczyt zachorowań obserwuje się w drugiej i trzeciej dekadzie życia.¹²

W badaniu przeprowadzonym w USA w 2023 roku, roczna zapadalność na narkolepsję wynosiła 2,6 przypadków na 100 000 osób.¹ Natomiast w Niemczech, według badania DORMIO, skumulowana zapadalność w okresie od 1 lipca 2017 r. do 30 czerwca 2018 r. wynosiła 0,83 przypadków na 100 000 osób.¹²

W Chinach, w ramach badania obserwacyjnego prowadzonego w latach 1990-2017, średnia roczna zapadalność na narkolepsję wynosiła 0,79 przypadków na 100 000 osobolat, a w okresie 2003-2017 wzrosła do 1,08 przypadków na 100 000 osobolat.¹

Różnice demograficzne w występowaniu narkolepsji

Dystrybucja narkolepsji pod względem płci nie jest jednoznaczna. Niektóre badania wskazują na częstsze występowanie narkolepsji u mężczyzn, z szacunkowym stosunkiem mężczyzn do kobiet wynoszącym 1,64:1.¹ Inne badania sugerują, że narkolepsja występuje z równą częstością u mężczyzn i kobiet.¹² W najnowszych badaniach prowadzonych w Szwecji zaobserwowano, że zarówno chorobowość, jak i zapadalność na narkolepsję były wyższe u kobiet niż u mężczyzn.¹

Rozkład wieku zachorowania na narkolepsję jest bimodalny, z najwyższym szczytem występującym około 15 roku życia i mniej wyraźnym szczytem około 36 roku życia. Jednakże narkolepsję stwierdzano również u dzieci w wieku od 2 lat.¹ Szanse na rozwój narkolepsji przed 5 rokiem życia są wyjątkowo małe. Narkolepsja występuje najczęściej u osób w wieku między 15 a 30 rokiem życia.¹

Nie ma silnych dowodów wskazujących, że ryzyko rozwoju narkolepsji jest wyższe w określonej grupie etnicznej. Narkolepsja występuje u osób każdej rasy.¹ Jednakże niektóre badania sugerują, że Afroamerykanie częściej prezentują narkolepsję bez katapleksji i w młodszym wieku.¹

Czynniki ryzyka i wpływ środowiskowy

Narkolepsja jest prawdopodobnie wywoływana przez ekspozycję na czynniki środowiskowe przed wystąpieniem objawów u osób genetycznie predysponowanych, podobnie jak w innych chorobach charakteryzujących się selektywną utratą komórek, takich jak choroba Parkinsona czy cukrzyca typu 1.¹

Występowanie narkolepsji jest zwiększone u krewnych pierwszego stopnia osób chorych, z szacowanym ryzykiem 1-2% (10-40 razy większym niż w populacji ogólnej).¹² Jednakże narkolepsja nie podąża za normalnymi wzorcami dziedziczenia, a zgodność wśród bliźniąt jednojajowych wynosi tylko 25-31%.¹²

Wśród czynników zwiększających ryzyko rozwoju narkolepsji wymienia się również: choroby tarczycy, cukrzycę oraz zaburzenia autoimmunologiczne.¹ Narkolepsja typu 1 (NT1) jest silnie związana z określonymi haplotypami ludzkich antygenów leukocytarnych (HLA), przy czym około 85% osób z objawami narkolepsji z katapleksją jest pozytywnych dla HLA DQB1*0602, często jednocześnie z HLA DR2 (DRB1*1501), a tylko 50% osób z narkolepsją bez katapleksji ma pozytywny haplotyp HLA DQB1*0602.¹

Narkolepsja po pandemii H1N1

Istotnym zagadnieniem w epidemiologii narkolepsji jest zwiększona częstość jej występowania po pandemii grypy H1N1 w 2009 roku. Badania z Pekinu w Chinach wykazały 3-krotny wzrost zachorowań na narkolepsję po pandemii H1N1 w 2009 roku, a częstość ta powróciła do poziomu wyjściowego po pandemii.¹

Wang i współpracownicy odkryli, że w porównaniu z okresem przed pandemią, zapadalność na narkolepsję była 4,17-krotnie wyższa w trakcie pandemii i 1,42-krotnie wyższa po pandemii.¹² Sugeruje to rolę wirusa A(H1N1)pdm09 w wyzwalaniu narkolepsji, choć potrzebne są dalsze badania, aby potwierdzić te zmiany i zbadać mechanizmy łączące wirusa grypy z narkolepsją.¹

W Europie Północnej zaobserwowano wzrost częstości występowania narkolepsji po szczepieniu szczepionką Pandemrix, opracowaną przeciwko pandemii H1N1 w 2009 roku. Zapadalność na narkolepsję u dzieci wzrosła z 0,79/100 000 do 6,3/100 000. Zwiększoną częstość występowania narkolepsji wykryto później we wszystkich krajach europejskich, w których stosowano Pandemrix, podczas gdy kraje stosujące inne marki szczepionek nie wykazywały zwiększonej częstości występowania narkolepsji związanej ze szczepieniami.¹²³

Niedawne badania wskazują również na potencjalny związek między wzrostem zachorowań na narkolepsję a wirusem grypy typu B Victoria, szczególnie u dzieci.¹²

Opóźnienie diagnostyczne i wpływ na życie pacjentów

Istotnym problemem w epidemiologii narkolepsji jest opóźnienie diagnostyczne. Średni czas od wystąpienia objawów do postawienia diagnozy wynosi zazwyczaj od 8 do 22 lat.¹ W jednym z ostatnich badań wykazano, że średnio upłynęło 14 lat od początku objawów do momentu diagnozy.¹ W przypadku dorosłych z narkolepsją opóźnienie diagnostyczne wynosi około 10 lat.¹

Narkolepsja może powodować znaczące problemy we wszystkich aspektach życia, w tym w szkole, pracy, relacjach i życiu domowym.¹ Osoby z nieleczoną narkolepsją mają trudności z funkcjonowaniem w szkole, pracy i domu. Są narażone na wysokie ryzyko zwolnienia z pracy lub wypadków drogowych. W rezultacie istnieje u nich wysokie ryzyko rozwoju stresu, lęku i depresji.¹

Pacjenci z narkolepsją często doświadczają problemów poznawczych, edukacyjnych, zawodowych i psychospołecznych związanych z nadmierną sennością w ciągu dnia. Występowanie tych problemów w kluczowych latach nastoletniej młodości, kiedy kształtuje się edukacja, obraz siebie i wybór zawodu, jest szczególnie druzgocące.¹

Obciążenie ekonomiczne związane z narkolepsją

Mimo stosunkowo niskiej chorobowości, narkolepsja wiąże się z upośledzeniem funkcjonowania na co dzień i ma uznane obciążenie społeczno-ekonomiczne, w tym zwiększone koszty medyczne w stosunku do populacji ogólnej, zwiększone ryzyko wypadków związanych z pracą lub pojazdami oraz obniżoną jakość życia.¹

Koszty bezpośrednie medyczne i farmaceutyczne związane z narkolepsją są dwukrotnie wyższe niż w populacji ogólnej.¹ Koszty wielu lat błędnej diagnozy lub niewłaściwego wykorzystania zasobów są głównymi problemami dla planów zdrowotnych, które płacą za te usługi. Jednak koszty te bledną w porównaniu z kosztem leków stosowanych w leczeniu narkolepsji.¹

Wnioski i perspektywy

Narkolepsja jest stosunkowo rzadkim zaburzeniem neurologicznym, jednak jej rozpoznanie rośnie dzięki zwiększonej świadomości poprzez media społecznościowe i rosnącym obawom dotyczącym zaburzeń snu.¹

W 2023 roku Międzynarodowa Klasyfikacja Zaburzeń Snu opublikowała nowe kryteria diagnostyczne, aby określić narkolepsję jako typ 1 lub typ 2 na podstawie objawów klinicznych, danych z testów obiektywnych i wartości laboratoryjnych. Nowy system umożliwił pracownikom służby zdrowia poprawę diagnozy i leczenia pacjentów z narkolepsją.¹

Identyfikacja modyfikowalnych czynników ryzyka pomoże zapobiegać tej chorobie.¹ Poprzez lepsze badania epidemiologiczne, społeczność naukowa i medyczna może poprawić nasze zbiorowe zrozumienie przyczyn i zwiększyć świadomość, wczesne rozpoznanie i leczenie narkolepsji.¹

Region	Chorobowość narkolepsji (na 100 000 osób)	Zapadalność (na 100 000 osobolat)	Źródło danych
USA i Europa (NT1)	25-50	0,74	Badania populacyjne
USA i Europa (NT2)	20-34	Dane ograniczone	Badania populacyjne
USA (2023)	37,7 (12,6 z katapleksją, 25,1 bez katapleksji)	2,6	Badanie populacyjne
Niemcy (2018)	3,1-9,1	0,83	Badanie DORMIO
Chiny (1990-2017)	Dane ograniczone	0,79	Badanie obserwacyjne
Izrael	0,2	Dane ograniczone	Badania epidemiologiczne
Japonia	Do 590	Dane ograniczone	Badania epidemiologiczne

¹²³⁴⁵⁶

Kolejne rozdziały

Zapraszamy do dalszego czytania naszego leksykonu.

Wybierz kolejny rozdział z menu poniżej, aby otworzyć nową podstronę kompedium wiedzy i uzyskać szczegółowe informację o leku, substancji lub chorobie.

Materiały źródłowe

#1 Clinical features and diagnosis of narcolepsy in adults – UpToDate
https://www.uptodate.com/contents/clinical-features-and-diagnosis-of-narcolepsy-in-adults/print
Narcolepsy is a clinical syndrome of chronic daytime sleepiness along with additional symptoms that may include cataplexy, disrupted nighttime sleep, sleep paralysis, and hypnogogic and hypnopompic hallucinations. […] The epidemiology, clinical features, etiology, and diagnosis of narcolepsy are reviewed here. […] Incidence and prevalence â Incidence and prevalence are best studied for narcolepsy type 1 (NT1). In population-based studies, the estimated incidence of NT1 is 0.74 per 100,000 person-years. Peak incidence is in the second and third decades. Prevalence estimates range from 25 to 50 per 100,000 people. Males and females are affected in equal proportions. […] Narcolepsy type 2 (NT2) appears to be slightly less common than NT1, with prevalence estimates ranging from 20 to 34 per 100,000 people.
#1 Narcolepsy: Practice Essentials, Background, Pathophysiology
https://emedicine.medscape.com/article/1188433-overview
The prevalence of narcolepsy in the US is 0.02%-0.18%, which is comparable to that of multiple sclerosis. The frequency among first-degree relatives is 1%-2% (10-40 times greater than that in the general population). The reported prevalence of narcolepsy in select populations is as follows: […] Narcolepsy with cataplexy affects 0.02% of adults worldwide. The reported prevalence of narcolepsy in select populations is as follows: […] The male-to-female ratio in narcolepsy is 1.64:1. The age-of-onset distribution is bimodal, with the highest peak occurring at 15 years and a less pronounced peak occurring at 36 years. However, narcolepsy has been reported in children as young as 2 years.
#1 Prevalence and incidence of narcolepsy symptoms in the US general population – PubMed
https://pubmed.ncbi.nlm.nih.gov/38149177/
Objective: The objectives of this study are to evaluate the prevalence and incidence of Narcolepsy type 1 and type 2 and to determine the prevalence of narcolepsy diagnosis criteria in the US general population. […] Participants were aged between 18 and 102 years of age (mean 45.8 17.9 years), 51.3 % were women. The prevalence of narcolepsy with cataplexy was 12.6 per 100,000 individuals (95 % C.I., 0 to 30) and narcolepsy without cataplexy was 25.1 per 100,000. The incidence per year was 2.6 per 100,000 individuals (95 % C.I., 0 to 11). […] Narcolepsy is a rare condition affecting 37.7/100,000 individuals (126,191 individuals in the current US population). Our US general population prevalence is in line with rates found in community-based studies but lower than what is reported in claim database studies.
#1 Epidemiology of Narcolepsy | SpringerLink
https://link.springer.com/chapter/10.1007/978-3-319-23739-8_4
Narcolepsy, first described in the 1880s, is characterized by excessive daytime sleepiness and commonly seen along with cataplexy, or episodic weakness, which occurs in 60-80 % of patients with narcolepsy. […] Current estimates indicate prevalence rates of about 1956 per 100,000 people in Europe and the USA, with some geographic areas of the world being much lower (e.g., Israel) and other areas being much higher (e.g., Japan). […] Some studies indicate that narcolepsy is more common among men than women. […] Narcolepsy is more common among first-degree relatives, but does not follow normal inheritance patterns with concordance among monozygotic twins being only 25-31 %. […] Through better epidemiological research, the scientific and medical community can improve our collective understanding of its causes and increase awareness, early recognition, and treatment of narcolepsy.
#1 Epidemiology, Diagnostics, and Treatment of Narcolepsy in Germany: The DORMIO Study
https://www.e-jsm.org/journal/view.php?number=309
This study aimed to investigate the prevalence, incidence, and real-world diagnostic and treatment patterns, healthcare resource utilization (HCRU), and associated costs of narcolepsy in Germany. […] The prevalence of narcolepsy was 3.19.1 per 100,000 persons within the German population; the cumulative incidence between July 1, 2017, and June 30, 2018, was 0.83/100,000 persons. […] The age- and sex-standardized prevalence of narcolepsy in the German population on June 30, 2018, were 5.3 cases per 100,000 persons when only considering patients diagnosed by specialists and 9.1/100,000 when including patients diagnosed by GPs. […] Overall, a prevalence of 3.19.1/100,000 persons can be estimated for Germany. The cumulative incidence evaluated for the period from July 1, 2017 to June 30, 2018, was 0.83 cases per 100,000 persons. […] The objective of our study was to generate real-world data on the epidemiology and treatment of patients with narcolepsy in Germany.
#1 867433 | Stanford Health Care
https://stanfordhealthcare.org/publications/867/867433.html
Increased incidence of narcolepsy was reported in children during the 2009 H1N1 pandemic following Pandemrix, a H1N1 flu vaccine. […] Using nationwide surveillance data from China (1990 to 2017), the epidemiology of narcolepsy was analyzed. […] Average annual incidence was 0.79 per 100,000 person-years (PY) from 1990 to 2017 and 1.08 per 100,000 PY from 2003 to 2017. Incidence increased 4.17 (95%CI 4.12, 4.22) and 1.42 (95%CI 1.41, 1.44) fold during and after the 2009 H1N1 pandemic when compared to baseline. […] Increased incidence of narcolepsy was observed during the 2009 H1N1 pandemic period. This is likely to be associated with the circulation of the wild-type A(H1N1)pdm09 virus.
#1 New publication on epidemiology and treatment patterns of patients with narcolepsy! | Quantify Research
https://quantifyresearch.com/2025/01/21/new-publication-on-epidemiology-and-treatment-patterns-of-patients-with-narcolepsy/
New publication on epidemiology and treatment patterns of patients with narcolepsy! […] An article using Swedish register data to study epidemiology, patient characteristics, and treatment patterns of patients with narcolepsy is hot off the press. […] The study found narcolepsy prevalence to be increasing during the study period, with both prevalence and incidence being higher in females than in males. […] At the time of the first narcolepsy diagnosis, not all patients used narcolepsy-related medications, potentially indicating a need for faster initiation of appropriate treatment following the index. […] Many incident patients were switched from the treatment they first initiated after diagnosis, suggesting that the currently available treatment options for narcolepsy are not sufficiently effective and/or have undesirable side effects.
#1
https://www.namcp.org/sleepdisorders/practicingdocs/html/disorders/narcolepsy/epidemiology.html
Narcolepsy has been shown to occur in people at nearly every age. However, some studies show narcolepsy occurs more frequently in certain age groups than others. The chances of developing narcolepsy before the age of five is extremely rare. Narcolepsy occurs most commonly in people between the ages of 15 and 30. Because narcolepsy can appear suddenly or gradually, some people will show mild symptoms for a few years before developing full blown narcolepsy.
#1
https://www.namcp.org/sleepdisorders/practicingdocs/html/disorders/narcolepsy/epidemiology.html
There are approximately 200,000 Americans who suffer from narcolepsy. This means that roughly 1 in 2000 people have narcolepsy. Some studies suggest that of the 200,000 people who are diagnosed with narcolepsy, up to 150,000 people go undiagnosed. There are several factors that have been identified which may increase the risk of developing narcolepsy. These include other family members who have been diagnosed with narcolepsy, certain thyroid disorders, diabetes, and autoimmune disorders. […] There are no strong statistics which indicate one ethnicity is at higher risk of developing narcolepsy than any other. Narcolepsy has been shown to occur in any person of any race. […] As of now, there are no strong statistics which indicate that one the risk of developing narcolepsy is higher in males or females.
#1 Narcolepsy | 5-Minute Clinical Consult
https://im.unboundmedicine.com/medicine/view/5-Minute-Clinical-Consult/1688548/2.0/Narcolepsy
Bimodal distribution; age of onset peak at 15 years and again at 35 years of age with male predominance. […] African Americans are more likely to present without cataplexy and at a younger age. […] Narcolepsy type 1: 25 to 50/100,000 people. […] Narcolepsy type 2: 20 to 34/100,000 people.
#1 The epidemiology of narcolepsy – PubMed
https://pubmed.ncbi.nlm.nih.gov/17310860/
Much has been learned about the pathophysiology of narcolepsy over the last several decades. […] The prevalence of narcolepsy with cataplexy has been examined in many studies and falls between 25 and 50 per 100,000 people. […] Information on incidence is limited, with 1 study finding the incidence of narcolepsy with cataplexy to be 0.74 per 100,000 person-years. […] As with other diseases characterized by selective cell loss, such as Parkinson disease or type 1 diabetes mellitus, narcolepsy is likely caused by environmental exposures before the age of onset in genetically susceptible individuals. […] Identification of modifiable risk factors will help to prevent this disease.
#1 Narcolepsy: A review amongst sleep disorders
https://www.oatext.com/narcolepsy-a-review-amongst-sleep-disorders.php
The incidence rate was highest in the second decade of life followed by third, fourth and fifth decades respectively. […] Most cases of narcolepsy are sporadic with some with familial clustering. […] Environmental factors have also played a role with 25% to 31% concordance in monozygotic twins. […] People who are first degree relatives are 10 to 40 times more vulnerable to develop narcolepsy compared to general population. […] Recent studies have also established a close link between narcolepsy and streptococcal infections and H1N1 vaccination. […] About 85% people having symptoms of narcolepsy with cataplexy are positive for HLA DQB1*0602, often simultaneously with HLA DR2 (DRB1*1501) and only 50 % with narcolepsy only have a positive HLA DQB1*0602 haplotype. […] However, there is lack of sufficient data in establishing routine HLA screening as a diagnostic test.
#1 Changed epidemiology of narcolepsy before, during, and after the 2009 H1N1 pandemic: a nationwide narcolepsy surveillance network study in mainland China, 1990-2017. – Thoracic and Sleep Group Queensland
https://thoracicandsleep.com.au/blog/changed-epidemiology-of-narcolepsy-before-during-and-after-the-2009-h1n1-pandemic-a-nationwide-narcolepsy-surveillance-network-study-in-mainland-china-1990-2017/
Changed epidemiology of narcolepsy before, during, and after the 2009 H1N1 pandemic: a nationwide narcolepsy surveillance network study in mainland China, 1990-2017. […] Prevalence is 20â50 per 100 000 population and incidence is approximately 1 per 100 000 person-years (PY) in the United States and European countries. […] Studies from Beijing, China found a 3-fold increase in narcolepsy onset following the 2009 H1N1 pandemic, and this increase returned to baseline following the pandemic. […] Wang et al found that compared to the pre-pandemic period, the incidence of narcolepsy was 4.17- and 1.42-fold higher during and postpandemic, respectively. […] They concluded that this study suggests the role of the A(H1N1) pdm09 virus in trigging narcolepsy. However they did concede that future research is needed to confirm these changes and investigate mechanisms linking the influenza virus to narcolepsy.
#1 Narcolepsy risk loci outline role of T cell autoimmunity and infectious triggers in narcolepsy | Nature Communications
https://www.nature.com/articles/s41467-023-36120-z
Narcolepsy type 1 (NT1) is caused by a loss of hypocretin/orexin transmission. Risk factors include pandemic 2009 H1N1 influenza A infection and immunization with Pandemrix. […] The sleep disorder type 1 narcolepsy (NT1) affects ~0.03% individuals across ethnic groups and populations and onset manifestation most commonly occurs in childhood or adolescence. […] Triggers of NT1 autoimmunity point to Influenza-A and, secondarily, Streptococcus pyogenes infections. Onset in children is abrupt and seasonal peaking between spring and summer, presumably following a winter infection. Further, multiple countries have reported increased incidence of NT1 46 months following the 2009 H1N1 (pH1N1) swine flu pandemic. Finally, immunization with Pandemrix, a pH1N1 vaccine created to prevent the 2009 pandemic, is an established trigger for NT1. Increased incidence following Pandemrix was first seen in Northern Europe, with incidence in children increasing from 0.79/100,000 to 6.3/100,000. Specificity is striking, as increased NT1 was later detected in all European countries where Pandemrix was used, whereas countries using other vaccine brands did not display vaccination-associated increases in incidence.
#1 2010 and 2013 incidence peaks in narcolepsy and idiopathic hypersomnia linked to type A H1N1 and type B Victoria influenza strains | medRxiv
https://www.medrxiv.org/content/10.1101/2024.04.19.24304365v1.full-text
Increased narcolepsy type 1 (NT1) incidence rates have been reported globally in 2010, and were linked to the type A H1N1 2009-2010 influenza pandemic and Pandemrix vaccination. […] A European child-specific NT1 incidence peak was additionally observed in 2013 post the H1N1 pandemic. […] Thus, the relationship between NT1 and influenza infection remains unclear. […] This study investigated annual European incidence patterns of all CDH in complete samples from multiple European centers, in relation to the severity of individual flu strains in preceding influenza seasons. […] 2010 and 2013 incidence peaks were present in NT1, and a 2010 children peak was unexpectedly found in the combined group of NT2 and IH. […] Both hypersomnolence groups exhibited a significantly positive relationship with preceding H1N1 influenza season severity and a negative relationship with H3N2 influenza.
#1 Narcolepsy: Diagnosis and management | Cleveland Clinic Journal of Medicine
https://www.ccjm.org/content/85/12/959
Narcolepsy type 1 is linked to a deficiency in hypocretin in the central nervous system. The prevalence of narcolepsy type 1 is between 25 and 100 per 100,000 people. In a Mayo Clinic study, the incidence of narcolepsy type 1 was estimated to be 0.74 per 100,000 person-years. Epidemiologic data on narcolepsy type 2 are sparse, but patients with narcolepsy without cataplexy are thought to represent only 36% of all narcolepsy patients. […] Diagnosis is often delayed, with the average time between the onset of symptoms and the diagnosis ranging from 8 to 22 years. With increasing awareness, the efficiency of the diagnostic process is improving, and this delay is expected to lessen accordingly. […] Symptoms most commonly arise in the second decade; but the age at onset ranges significantly, between the first and fifth decades. Narcolepsy has a bimodal distribution in incidence, with the biggest peak at approximately age 15 and second smaller peak in the mid-30s. Some studies have suggested a slight male predominance.
#1 Narcolepsy: Symptoms, Diagnosis, and Treatment Options
https://brainfoundation.org.au/disorders/narcolepsy/
Narcolepsy is a frequent disorder, the second leading cause of excessive daytime sleepiness diagnosed by sleep centres after sleep apnea. Studies on the epidemiology of narcolepsy show an incidence of 0.2 to 1.6 per thousand in European countries, Japan and the United States. […] In many cases diagnosis is not made until many years after the onset of symptoms. In one recent study, it took on average 14 years from the onset of symptoms to time of diagnosis. […] Early diagnosis and treatment, however, are important to the physical and mental well-being of the sufferer, since studies have shown that even treated narcoleptic patients are often markedly psychosocially impaired in the area of work, leisure, interpersonal relations, and are more prone to accidents.
#1 Narcolepsy – Wikipedia
https://en.wikipedia.org/wiki/Narcolepsy
Estimates of frequency range from 0.2 per 100,000 in Israel to 600 per 100,000 in Japan. […] In the United States, narcolepsy is estimated to affect as many as 200,000 Americans, but fewer than 50,000 are diagnosed. The prevalence of narcolepsy is about 1 per 2,000 persons. […] Narcolepsy can occur in both men and women at any age, although typical symptom onset occurs in adolescence and young adulthood. There is about a ten-year delay in diagnosing narcolepsy in adults. […] Cognitive, educational, occupational, and psychosocial problems associated with the excessive daytime sleepiness of narcolepsy have been documented. For these to occur in the crucial teen years when education, development of self-image, and development of occupational choice are taking place is especially devastating.
#1 Narcolepsy: Information for Physicians : Ottawa-Carleton, ON : eMentalHealth.ca
https://primarycare.ementalhealth.ca/index.php?m=fpArticle&ID=76881
Epidemiology […] Prevalence […] 1 in 2000 people (0.05% of the population). […] Onset […] Symptoms can start at any age, but most often starts in adolescence. […] Peak periods of onset appear to be age 15 and age 35 (Dauvilliers, 2001). […] […] […] As a result, narcolepsy can cause significant problems with all aspects of life including school, work, relationships and home life. […] […] […] Those with untreated narcolepsy struggle with functioning at school, work and home. They are at a high risk of being fired or getting into motor vehicle accidents. As a result, they are at a high risk of developing stress, anxiety and depression. […] […] […] Even when people see health professionals, they are often misdiagnosed or told they are lazy and inattentive, or that they have conditions such as epilepsy, substance use problems, attention deficit disorder, depression, anxiety or even schizophrenia. These stigmas can often continue to persist by friends, family and colleagues after diagnosis. They often struggle for an average of 10 or more years before symptoms are identified and diagnosed.
#1 The Medical and Economic Burden of Narcolepsy: Implications for Managed Care
https://www.ahdbonline.com/articles/2421-the-medical-and-economic-burden-of-narcolepsy-implications-for-managed-care
Narcolepsy is believed to be an autoimmune disorder with destruction of hypocretin-producing neurons in the lateral hypothalamus. The prevalence of narcolepsy is approximately 0.05%, and onset generally occurs during the first 2 decades of life. […] Although the prevalence of narcolepsy is low, between 0.02% and 0.06% in industrialized countries, the associated healthcare costs are disproportionately high, with direct medical and pharmacy costs that are twice that of the general population. […] Despite its low prevalence, narcolepsy is associated with impaired function on a daily basis and has a recognized socioeconomic burden, including increased medical costs relative to the general population, an increased risk for work-related or vehicular accidents, and reduced quality of life. […] Although narcolepsy has an early onset, a diagnostic delay that often exceeds 10 years from the time of symptom onset has consistently been reported in the literature, suggesting that narcolepsy is underrecognized and underdiagnosed.
#1 The Medical and Economic Burden of Narcolepsy: Implications for Managed Care
https://www.ahdbonline.com/articles/2421-the-medical-and-economic-burden-of-narcolepsy-implications-for-managed-care
The lack of easily measurable and reliable biomarkers also adds to the challenge of managing patients with this disease. […] The costs of many years of misdiagnosis or inappropriate resource utilization are major concerns to health plans that are paying for these services. […] The doubling of direct costs to patients with narcolepsy compared with controls without the disease speaks to the need for health plans to assist in the management of these patients; however, these costs pale in comparison with the cost of the drugs to treat narcolepsy. […] The lack of easily measurable and reliable biomarkers also adds to the challenge of managing patients with this disease.
#1 Opinion About Narcolepsy and Disability Diagnosis
https://www.sleepmedres.org/journal/view.php?doi=10.17241/smr.2024.02404
Narcolepsy is a sleep disorder characterized by excessive daytime sleepiness and cataplexy referred to as type 1 narcolepsy. […] Although narcolepsy is a rare disease due to its limited prevalence, its recognition is increasing, driven by heightened awareness through social media and growing concerns about sleep disorders. […] According to data from the Korean National Health Insurance from 2010 to 2019, there were approximately 8700 patients undergoing treatment for narcolepsy, with about 5900 diagnosed with type 1 narcolepsy. […] We can estimate that 5% 10% of type 1 narcolepsy patients (approximately 295590 patients) might require disability diagnoses. […] The criteria for diagnosing disability due to narcolepsy should reflect the severity of narcolepsy symptoms such as daytime sleepiness and cataplexy severity, and the impairment these cause in daily functioning. […] Including accompanying psychiatric symptoms in the current disability diagnosis does not provide an accurate basis for assessing disability in narcolepsy patients.
#1
https://learning.aan.com/courses/81395
Narcolepsy is a condition that is often misdiagnosed and underdiagnosed due to overlapping clinical symptoms with other neurological disorders. This leads to patients facing unnecessary financial and socioeconomic burdens and reduced quality of life. […] In 2023, the International Classification of Sleep Disorders published new diagnostic criteria to delineate narcolepsy into Type 1 or Type 2 based on clinical symptoms, objective testing data and laboratory values. The new system enabled healthcare providers to improve diagnosis and treatment of patients with narcolepsy. […] Our goals for this video are to enhance knowledge of narcolepsy epidemiology, clinical presentation, diagnostic criteria and treatment. With this information, we aim to help providers better counsel patients about the pathophysiology, diagnosis and treatment of narcolepsy to patients and overall general public interested in this condition. […] Understand the prevalence and clinical diagnostic criteria of different types of narcolepsy.
#1 Epidemiology of Narcolepsy: Development of the Ullanlinna Narcolepsy S
https://www.taylorfrancis.com/chapters/edit/10.3109/9781420019254-17/epidemiology-narcolepsy-development-ullanlinna-narcolepsy-scale-christer-hublin
Until the beginning of the 1990s there were only about one dozen studies on the prevalence of narcolepsy, the earliest published in 1945 by Solomon (1). Despite great differences in definitions of the disorder, study populations, diagnostic procedure, and other methodological aspects, the results gave quite a remarkable 2500-fold difference in the prevalence, ranging from 0.23 to 590 narcoleptic subjects per 100,000 of population. Nevertheless, 95% confidence intervals could be calculated in eight studies and they overlapped or nearly overlapped in seven of them, indicating that the prevalence probably is in the range of 10-100 per 100,000.
#2 The epidemiology of narcolepsy – PubMed
https://pubmed.ncbi.nlm.nih.gov/17310860/
Much has been learned about the pathophysiology of narcolepsy over the last several decades. […] The prevalence of narcolepsy with cataplexy has been examined in many studies and falls between 25 and 50 per 100,000 people. […] Information on incidence is limited, with 1 study finding the incidence of narcolepsy with cataplexy to be 0.74 per 100,000 person-years. […] As with other diseases characterized by selective cell loss, such as Parkinson disease or type 1 diabetes mellitus, narcolepsy is likely caused by environmental exposures before the age of onset in genetically susceptible individuals. […] Identification of modifiable risk factors will help to prevent this disease.
#2 Prevalence and incidence of narcolepsy symptoms in the US general population – PubMed
https://pubmed.ncbi.nlm.nih.gov/38149177/
Objective: The objectives of this study are to evaluate the prevalence and incidence of Narcolepsy type 1 and type 2 and to determine the prevalence of narcolepsy diagnosis criteria in the US general population. […] Participants were aged between 18 and 102 years of age (mean 45.8 17.9 years), 51.3 % were women. The prevalence of narcolepsy with cataplexy was 12.6 per 100,000 individuals (95 % C.I., 0 to 30) and narcolepsy without cataplexy was 25.1 per 100,000. The incidence per year was 2.6 per 100,000 individuals (95 % C.I., 0 to 11). […] Narcolepsy is a rare condition affecting 37.7/100,000 individuals (126,191 individuals in the current US population). Our US general population prevalence is in line with rates found in community-based studies but lower than what is reported in claim database studies.
#2
https://www.namcp.org/sleepdisorders/practicingdocs/html/disorders/narcolepsy/epidemiology.html
There are approximately 200,000 Americans who suffer from narcolepsy. This means that roughly 1 in 2000 people have narcolepsy. Some studies suggest that of the 200,000 people who are diagnosed with narcolepsy, up to 150,000 people go undiagnosed. There are several factors that have been identified which may increase the risk of developing narcolepsy. These include other family members who have been diagnosed with narcolepsy, certain thyroid disorders, diabetes, and autoimmune disorders. […] There are no strong statistics which indicate one ethnicity is at higher risk of developing narcolepsy than any other. Narcolepsy has been shown to occur in any person of any race. […] As of now, there are no strong statistics which indicate that one the risk of developing narcolepsy is higher in males or females.
#2 Narcolepsy – Wikipedia
https://en.wikipedia.org/wiki/Narcolepsy
Estimates of frequency range from 0.2 per 100,000 in Israel to 600 per 100,000 in Japan. […] In the United States, narcolepsy is estimated to affect as many as 200,000 Americans, but fewer than 50,000 are diagnosed. The prevalence of narcolepsy is about 1 per 2,000 persons. […] Narcolepsy can occur in both men and women at any age, although typical symptom onset occurs in adolescence and young adulthood. There is about a ten-year delay in diagnosing narcolepsy in adults. […] Cognitive, educational, occupational, and psychosocial problems associated with the excessive daytime sleepiness of narcolepsy have been documented. For these to occur in the crucial teen years when education, development of self-image, and development of occupational choice are taking place is especially devastating.
#2 Epidemiology, Diagnostics, and Treatment of Narcolepsy in Germany: The DORMIO Study
http://e-jsm.org/journal/view.php?number=309
This study aimed to investigate the prevalence, incidence, and real-world diagnostic and treatment patterns, healthcare resource utilization (HCRU), and associated costs of narcolepsy in Germany. […] The prevalence of narcolepsy was 3.19.1 per 100,000 persons within the German population; the cumulative incidence between July 1, 2017, and June 30, 2018, was 0.83/100,000 persons. […] The age- and sex-standardized prevalence of narcolepsy in the German population on June 30, 2018, were 5.3 cases per 100,000 persons when only considering patients diagnosed by specialists and 9.1/100,000 when including patients diagnosed by GPs. […] Overall, a prevalence of 3.19.1/100,000 persons can be estimated for Germany. The cumulative incidence evaluated for the period from July 1, 2017 to June 30, 2018, was 0.83 cases per 100,000 persons.
#2 Narcolepsy – Neurologic Disorders – Merck Manual Professional Edition
https://www.merckmanuals.com/professional/neurologic-disorders/sleep-and-wakefulness-disorders/narcolepsy
Narcolepsy is characterized by chronic excessive daytime sleepiness, often with sudden loss of muscle tone (cataplexy). […] In Europe, Japan, and the United States, incidence is 0.2 to 1.6/1000. […] Narcolepsy is equally common in both sexes. […] Narcolepsy is strongly associated with specific human leukocyte antigen (HLA) haplotypes, but the cause is not thought to be genetic. […] Concordance in twins is low (approximately 25% in type 1 narcolepsy), suggesting a prominent role for environmental factors, which often trigger the disorder. […] A delay of 10 years from onset of symptoms to diagnosis of narcolepsy is common. […] A history of cataplexy strongly suggests type 1 narcolepsy in patients with EDS. […] Narcolepsy type 1 is diagnosed if patients also have cataplexy; type 2 is diagnosed if patients do not have cataplexy. EDS occurs in patients with narcolepsy type 1 or type 2. […] Other disorders that can cause chronic EDS are usually suggested by the history and physical examination; brain imaging and blood and urine tests can confirm the diagnosis.
#2 Epidemiology of Narcolepsy around the World
https://www.sleepeval.com/dyssomnia/narcolepsy_worldEpidemiology.html
Furthermore, it should be stressed that epidemiological surveys completed with polysomnography yield lower prevalences than studies based only on questionnaires. […] The importance of genetic factors in narcolepsy has been addressed for more than 60 years. However, the results varied from six to 40 percent of narcoleptic individuals who have a close relative with the disease. […] The risk for narcolepsy was estimated to be between 10 to 40 times higher among families with a narcoleptic member than in the general population. […] Limitations from existing classifications pose serious difficulties in studying narcolepsy in the general population. The use of too large criteria inflates the prevalence.
#2 Narcolepsy: A review amongst sleep disorders
https://www.oatext.com/narcolepsy-a-review-amongst-sleep-disorders.php
The incidence rate was highest in the second decade of life followed by third, fourth and fifth decades respectively. […] Most cases of narcolepsy are sporadic with some with familial clustering. […] Environmental factors have also played a role with 25% to 31% concordance in monozygotic twins. […] People who are first degree relatives are 10 to 40 times more vulnerable to develop narcolepsy compared to general population. […] Recent studies have also established a close link between narcolepsy and streptococcal infections and H1N1 vaccination. […] About 85% people having symptoms of narcolepsy with cataplexy are positive for HLA DQB1*0602, often simultaneously with HLA DR2 (DRB1*1501) and only 50 % with narcolepsy only have a positive HLA DQB1*0602 haplotype. […] However, there is lack of sufficient data in establishing routine HLA screening as a diagnostic test.
#2 867433 | Stanford Health Care
https://stanfordhealthcare.org/publications/867/867433.html
Increased incidence of narcolepsy was reported in children during the 2009 H1N1 pandemic following Pandemrix, a H1N1 flu vaccine. […] Using nationwide surveillance data from China (1990 to 2017), the epidemiology of narcolepsy was analyzed. […] Average annual incidence was 0.79 per 100,000 person-years (PY) from 1990 to 2017 and 1.08 per 100,000 PY from 2003 to 2017. Incidence increased 4.17 (95%CI 4.12, 4.22) and 1.42 (95%CI 1.41, 1.44) fold during and after the 2009 H1N1 pandemic when compared to baseline. […] Increased incidence of narcolepsy was observed during the 2009 H1N1 pandemic period. This is likely to be associated with the circulation of the wild-type A(H1N1)pdm09 virus.
#2 ECDC â VAESCO investigation into narcolepsy
https://www.ecdc.europa.eu/en/news-events/ecdc-vaesco-investigation-narcolepsy
In the second half of 2010 ECDC, has been working with the VAESCO Consortium (Vaccine Adverse Events Monitoring and Communication) to investigate potential risk factors for narcolepsy including infections and vaccinations. […] The incidence has been estimated at around 0.74 – 1.37 per 100 000 person-years depending on the way the condition is defined. However, because narcolepsy is enduring, prevalence rates are much higher. […] In August 2010 the Finnish National Institute for Health and Welfare (THL) recommended that vaccination with Pandemrix vaccine should be discontinued in Finland until an explanation was found for an observed rise in cases of narcolepsy among children and adolescents vaccinated against 2009 pandemic influenza. […] The available data were reviewed by the Committee for Medicinal Products for Human Use (CHMP) in September which concluded that the available evidence was insufficient to determine whether there was any link between Pandemrix and reports of narcolepsy, but that further studies were urgently needed to fully understand this issue.
#2 2010 and 2013 incidence peaks in narcolepsy and idiopathic hypersomnia linked to type A H1N1 and type B Victoria influenza strains | medRxiv
https://www.medrxiv.org/content/10.1101/2024.04.19.24304365v1.full-text
NT1 was additionally significantly positively correlated with influenza type B Victoria in the Netherlands and showed highest correlation in children. […] Besides H1N1 influenza, the temporal association and severity correlation suggest that influenza type B Victoria may be a novel potential trigger for NT1 that requires further investigation. […] We additionally provide insights into possible immune-related pathophysiologies of NT2 and IH associated with the 2009-2010 H1N1 influenza pandemic. […] Further immunological investigations are warranted to unravel the complexities of these relationships and their implications for CDH.
#2 Clinical features and diagnosis of narcolepsy in adults – UpToDate
https://www.uptodate.com/contents/clinical-features-and-diagnosis-of-narcolepsy-in-adults/print
Narcolepsy is a clinical syndrome of chronic daytime sleepiness along with additional symptoms that may include cataplexy, disrupted nighttime sleep, sleep paralysis, and hypnogogic and hypnopompic hallucinations. […] The epidemiology, clinical features, etiology, and diagnosis of narcolepsy are reviewed here. […] Incidence and prevalence â Incidence and prevalence are best studied for narcolepsy type 1 (NT1). In population-based studies, the estimated incidence of NT1 is 0.74 per 100,000 person-years. Peak incidence is in the second and third decades. Prevalence estimates range from 25 to 50 per 100,000 people. Males and females are affected in equal proportions. […] Narcolepsy type 2 (NT2) appears to be slightly less common than NT1, with prevalence estimates ranging from 20 to 34 per 100,000 people.
#3 Epidemiology of Narcolepsy: Development of the Ullanlinna Narcolepsy S
https://www.taylorfrancis.com/chapters/edit/10.3109/9781420019254-17/epidemiology-narcolepsy-development-ullanlinna-narcolepsy-scale-christer-hublin
Until the beginning of the 1990s there were only about one dozen studies on the prevalence of narcolepsy, the earliest published in 1945 by Solomon (1). Despite great differences in definitions of the disorder, study populations, diagnostic procedure, and other methodological aspects, the results gave quite a remarkable 2500-fold difference in the prevalence, ranging from 0.23 to 590 narcoleptic subjects per 100,000 of population. Nevertheless, 95% confidence intervals could be calculated in eight studies and they overlapped or nearly overlapped in seven of them, indicating that the prevalence probably is in the range of 10-100 per 100,000.
#3 Narcolepsy associated with pandemic vaccination – Health Protection Surveillance Centre
https://www.hpsc.ie/a-z/respiratory/influenza/seasonalinfluenza/publications/influenzavaccinationpublications/narcolepsyassociatedwithpandemicvaccination/
Dr James Reilly T.D., Minister for Health, today (19/4/12) published a study commissioned by his Department to investigate a possible association between narcolepsy and the vaccine Pandemrix. […] The study found an increased risk of developing narcolepsy in the 5-19 years age group who had received the Pandemrix vaccine compared with those who had not received that vaccine. […] These results are very similar to those seen in Sweden and Finland with a clear increased risk evident from the available data. […] International experts agree that a number of factors are likely to have contributed to the increased risk and a number of international studies are continuing which should provide additional information.
#3 Prevalence and incidence of narcolepsy symptoms in the US general population – PubMed
https://pubmed.ncbi.nlm.nih.gov/38149177/
Objective: The objectives of this study are to evaluate the prevalence and incidence of Narcolepsy type 1 and type 2 and to determine the prevalence of narcolepsy diagnosis criteria in the US general population. […] Participants were aged between 18 and 102 years of age (mean 45.8 17.9 years), 51.3 % were women. The prevalence of narcolepsy with cataplexy was 12.6 per 100,000 individuals (95 % C.I., 0 to 30) and narcolepsy without cataplexy was 25.1 per 100,000. The incidence per year was 2.6 per 100,000 individuals (95 % C.I., 0 to 11). […] Narcolepsy is a rare condition affecting 37.7/100,000 individuals (126,191 individuals in the current US population). Our US general population prevalence is in line with rates found in community-based studies but lower than what is reported in claim database studies.
#4 Epidemiology, Diagnostics, and Treatment of Narcolepsy in Germany: The DORMIO Study
https://www.e-jsm.org/journal/view.php?number=309
This study aimed to investigate the prevalence, incidence, and real-world diagnostic and treatment patterns, healthcare resource utilization (HCRU), and associated costs of narcolepsy in Germany. […] The prevalence of narcolepsy was 3.19.1 per 100,000 persons within the German population; the cumulative incidence between July 1, 2017, and June 30, 2018, was 0.83/100,000 persons. […] The age- and sex-standardized prevalence of narcolepsy in the German population on June 30, 2018, were 5.3 cases per 100,000 persons when only considering patients diagnosed by specialists and 9.1/100,000 when including patients diagnosed by GPs. […] Overall, a prevalence of 3.19.1/100,000 persons can be estimated for Germany. The cumulative incidence evaluated for the period from July 1, 2017 to June 30, 2018, was 0.83 cases per 100,000 persons. […] The objective of our study was to generate real-world data on the epidemiology and treatment of patients with narcolepsy in Germany.
#5 867433 | Stanford Health Care
https://stanfordhealthcare.org/publications/867/867433.html
Increased incidence of narcolepsy was reported in children during the 2009 H1N1 pandemic following Pandemrix, a H1N1 flu vaccine. […] Using nationwide surveillance data from China (1990 to 2017), the epidemiology of narcolepsy was analyzed. […] Average annual incidence was 0.79 per 100,000 person-years (PY) from 1990 to 2017 and 1.08 per 100,000 PY from 2003 to 2017. Incidence increased 4.17 (95%CI 4.12, 4.22) and 1.42 (95%CI 1.41, 1.44) fold during and after the 2009 H1N1 pandemic when compared to baseline. […] Increased incidence of narcolepsy was observed during the 2009 H1N1 pandemic period. This is likely to be associated with the circulation of the wild-type A(H1N1)pdm09 virus.
#6 Narcolepsy – Wikipedia
https://en.wikipedia.org/wiki/Narcolepsy
Estimates of frequency range from 0.2 per 100,000 in Israel to 600 per 100,000 in Japan. […] In the United States, narcolepsy is estimated to affect as many as 200,000 Americans, but fewer than 50,000 are diagnosed. The prevalence of narcolepsy is about 1 per 2,000 persons. […] Narcolepsy can occur in both men and women at any age, although typical symptom onset occurs in adolescence and young adulthood. There is about a ten-year delay in diagnosing narcolepsy in adults. […] Cognitive, educational, occupational, and psychosocial problems associated with the excessive daytime sleepiness of narcolepsy have been documented. For these to occur in the crucial teen years when education, development of self-image, and development of occupational choice are taking place is especially devastating.